南开大学生命科学学院沈浩晟教授团队招聘博士及博士后 导师介绍 ： 沈浩晟 ，即将入职南开大学生命科学学院微生物学教授。 2016 年于南开大学获学士学位，2021 年于新 加坡国立大学获博士学位，2025 年获国家自然科学基金海外高层次人才计划。主要从事合成生物学、微生 物组学，以及益生菌活体药在肿瘤、代谢疾病治疗和鼻脑药物递送方向的研究与转化应用。近五年在 Cell、Nature Communications、Advanced Drug Delivery Reviews 等顶级期刊发表多篇论文。 研究方向 ： 基于微生物组学与合成生物学，解析共生菌与宿主的互作机制，挖掘活体益生菌药物在肿瘤、代谢性疾病 及脑部疾病治疗中的研究和转化应用。以探索微生物组 -人体互作机制为核心，专注于以下方向： 1）利用化学修饰或基因编辑改造肿瘤共生微生物，实现对抗肿瘤药物的表面装载与原位表达。利用共生菌 与肿瘤的互作，局部提高肿瘤周围药物浓度，降低系统性毒性，实现共生菌介导的黏膜端抗肿瘤药物靶向 递送； 2）基于植物乳杆菌与宿主嗅觉黏膜的结合特性，实现其对不同药物分子的装载与递送，进一步完善鼻腔共 生菌介导的鼻至脑药物递送系统 ...

Group 1: Human Monoclonal Antibodies Against Monkeypox Virus - A study published in Cell identified two human monoclonal antibodies (mAb 975 and mAb 981) that provide potential protection against the monkeypox virus in mice and macaques [5][7] - The research revealed high-resolution structures of the antibody-antigen complex, providing insights into the molecular mechanism of how these antibodies recognize the monkeypox virus [7] - This study offers a conceptual validation for the use of these monoclonal antibodies as therapeutic candidates and may inform future vaccine design [7] Group 2: High-Resolution Microbial and Antibiotic Resistance Gene Mapping - A study from Fudan University characterized a high-resolution map of mammalian microbiomes and antibiotic resistance genes (ARGs), identifying over 7,000 previously unreported bacterial species [9][11] - The research found that bacterial strains are widely shared across different hosts and geographic regions, indicating potential cross-host transmission [11] - A total of 521 ARGs were detected, with 157 being highly homologous between human and mammalian microbiomes, highlighting the prevalence of certain ARGs in mammalian microbiomes [11] Group 3: Mechanisms of Nociceptor Resilience to Excitotoxicity - A study from UCSF discovered that reduced expression of mitochondrial electron transport chain components enhances nociceptor resilience to excitotoxicity and oxidative stress [14][17] - The findings suggest that nociceptors actively lower mitochondrial activity to survive harmful stimuli, which has implications for understanding neuropathological consequences in conditions like diabetes and chemotherapy [17][18] Group 4: Localized Mitochondrial Translation - MIT researchers developed a tool called LOCL-TL to monitor localized translation in mammalian cells, revealing two distinct mechanisms of translation on the mitochondrial outer membrane [20][24] - This tool is expected to facilitate research on localized translation's role in various biological processes and its implications in diseases such as cancer and neurological disorders [24] Group 5: Hepatocyte Metabolic Adaptations During Pregnancy and Lactation - A study from Peking University described adaptive changes in mouse hepatocytes during pregnancy and lactation, identifying a "pregnancy clock" that regulates metabolic changes [26][29] - The research highlighted the importance of specific proteins in maintaining liver adaptability during pregnancy and lactation, with potential implications for maternal-fetal health and livestock management [29] Group 6: New Spatial Transcriptomics Technology - Stereo-seq V2 - A new spatial transcriptomics technology, Stereo-seq V2, was introduced, enabling high-resolution, in situ analysis of host-microbe interactions in FFPE samples [32][35] - This technology overcomes limitations of traditional methods, allowing for comprehensive analysis of cellular gene expression and interactions with pathogens [35]

Group 1 - The 112th National Sugar and Wine Products Trade Fair was held in Chengdu, attracting over 6,600 participating companies, including Saibogao, which was recognized for its contributions to the high-quality development of the Chinese food industry [1][2] - Saibogao was awarded as a "Growth-Oriented Enterprise" and a "Consumer Trend Leader Brand" at the event, highlighting its innovative approach and product quality [1][2] - The event featured a "Trends Release" conference that gathered over 350 industry leaders, showcasing the future landscape of the Chinese food industry through five key segments: trends, investment, product, recruitment, and innovation [2] Group 2 - Saibogao's Microbiome Center Director, Cai Feng, delivered a presentation titled "Technological Breakthroughs Defining New Standards for Probiotics," discussing the company's innovative approaches in child growth and development management [3] - Clinical trials showed that children taking Saibogao's patented strain, Bifidobacterium animalis subsp. lactis BL-11, experienced an average height increase of approximately 2.6 cm over three months compared to the placebo group [3] - The clinical study was conducted in collaboration with top international research institutions, and findings were published in the journal "Frontiers in Nutrition" [3] Group 3 - A recent project led by Saibogao's parent company and Huazhong University of Science and Technology aims to evaluate the effectiveness and safety of Bifidobacterium animalis subsp. lactis BL-11 in improving the height of short children through a randomized, double-blind, multi-center clinical study [4] - Saibogao focuses on microbiome research and child health management, with its core product, "Saibogao BL-11 Probiotic Oil Drops," filling a gap in the domestic market for children's growth and development [4] - Long-term use of Saibogao's probiotics is reported to significantly improve children's gut health and nutrient absorption, promoting growth factors essential for height development [4] Group 4 - Cai Feng emphasized that microbiome research could be the key to addressing challenges in child growth and development, indicating Saibogao's commitment to increasing research investment for the benefit of Chinese families [5]